Entry Detail

General Information

Database ID: LDA0006840
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Yes

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:TCF7
Full Name:transcription factor 7
Category:LncRNA
Species:Homo sapiens
Synonyms:TCF-1
Chromosome:5
Strand:+
Coordinate:
Start Site(bp):134108218End Site(bp):134148210
External Links:
Ensembl ID:ENSG00000081059
Ensembl Transcript ID:N/A
Entrez Gene:6932.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:4   
More Information
Causal Disease Number:4
Network:
Top Causal Diseases:
Ovarian Neoplasms  (Score: 0.731059)
Multiple Myeloma  (Score: 0.731059)
Ovarian Neoplasms  (Score: 0.731059)
Multiple Myeloma  (Score: 0.731059)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:9538D009101
Disease Name:multiple myelomaMultiple Myeloma
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A myeloid neoplasm that is located_in the plasma cells in bone marrow.A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Alias:Multiple Myeloma//Multiple Myelomas//Myelomas, Multiple//Myeloma, Multiple//Myeloma, Plasma-Cell//Myeloma, Plasma Cell//Myelomas, Plasma-Cell//Plasma-Cell Myeloma//Plasma-Cell Myelomas//Myelomatosis//Myelomatoses//Plasma Cell Myeloma//Cell Myeloma, Plasma//Cell Myelomas, Plasma//Myelomas, Plasma Cell//Plasma Cell Myelomas//Kahler Disease//Disease, Kahler//Myeloma-Multiple//Myeloma Multiple//Myeloma-Multiples

 

Disease Association Statistics

Total Associated ncRNA Number:180   
More Information
Causal ncRNA Number:96
Network:
Top Causal ncRNAs:
NEAT1  (Score: 1)
NEAT1  (Score: 1)
CDKN2B-AS1  (Score: 0.999893)
CDKN2B-AS1  (Score: 0.999893)
ST3GAL6-AS1  (Score: 0.999893)
MALAT1  (Score: 0.999893)
MALAT1  (Score: 0.999893)
ST3GAL6-AS1  (Score: 0.999893)
hsa_circ_0007841  (Score: 0.985791)
lnc-TCF7  (Score: 0.985791)
More Information

 

Evidence Support

Strong Evidence:CCK8//qRT-PCR//Transfection
Weak Evidence:

 

Reference

[1] PubMed ID:33552250
Disease Name:Multiple Myeloma
Sample:patients with MM
Dysfunction Pattern:Interaction( miR-200c )
Validated Method:CCK8//qRT-PCR//Transfection
Description:The results demonstrated that lncRNA TCF7 expression was upregulated in patients with MM compared with controls, and the receiver operating characteristic curve revealed that lncRNA TCF7 could distinguish patients with MM from controls with an area under the curve of 0.793 (95% CI, 0.725-0.861). lncRNA TCF7 also promoted cell proliferation, whereas it reduced cell apoptosis and miR-200c expression in RPMI-8226 and U-266 cells. In conclusion, the present results suggested that lncRNA TCF7 may be used as a potential biomarker and as a treatment target for MM.
Causality:Yes
Causal Description: lncRNA TCF7 also promoted cell proliferation, whereas it reduced cell apoptosis and miR-200c expression in RPMI-8226 and U-266 cells. In conclusion, the present results suggested that lncRNA TCF7 may be used as a potential biomarker and as a treatment target for MM.
Clinical-realted Application:The results demonstrated that lncRNA TCF7 expression was upregulated in patients with MM compared with controls, and the receiver operating characteristic curve revealed that lncRNA TCF7 could distinguish patients with MM from controls with an area under the curve of 0.793 (95% CI, 0.725-0.861). In patients with MM, high lncRNA TCF7 expression was associated with higher β2-microglobulin, more advanced International Staging System stage and increased t (14; 16) mutations.